Non-anilinic derivatives of isothiazol-3(2H)-one...

Details Non-anilinic derivatives of isothiazol-3(2H)-one... Non-anilinic derivatives of isothiazol-3(2H)-one...

2011-06-14

2011-06-14

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252050, C514S256000, C514S326000, C514S342000, C514S372000, C514S397000

Reexamination Certificate

active

07960380

ABSTRACT:
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

REFERENCES:
patent: 2003/0195238 (2003-10-01), Gil et al.
patent: 1069110 (2001-01-01), None
patent: 2001163786 (2001-06-01), None
patent: 9708143 (1997-03-01), None
patent: 0021927 (2000-04-01), None
patent: 0054759 (2000-09-01), None
patent: 0103705 (2001-01-01), None
patent: 0174771 (2001-10-01), None
patent: 0246183 (2002-06-01), None
patent: 03031440 (2003-04-01), None
patent: 2004111022 (2004-12-01), None
patent: 2005005416 (2005-01-01), None
patent: 2005005417 (2005-01-01), None
patent: 2005035551 (2005-04-01), None
Laffitte et al., “Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue,” PNAS (2003) 100(9):5419-5424.
Office Action dated Dec. 22, 2008 received in copending U.S. Appl. No. 11/813,489.
Patani, George, A. Bioisosterism: A rational approach in drug design. Chem. Rev. 96 (1996) 3147-3176.
“Atherosclerosis.” Retrieved online via Internet [Dec. 13, 2008] http://www.nlm.nih.gov/medlineplus/ency/article/000171. htm.
Office Action dated Dec. 22, 2008 received in copending U.S. Appl. No. 11/813,458.
Notice of Allowance dated Apr. 16,2009 received in U.S. Appl. No. 11/813,481.
Office Action dated Jun. 22, 2010 received in copending U.S. Appl. No. 12/507,924.

Affiliated with

Also associated with

Rating

Non-anilinic derivatives of isothiazol-3(2H)-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-anilinic derivatives of isothiazol-3(2H)-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-anilinic derivatives of isothiazol-3(2H)-one... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2673603